Massively parallel sequencing of maternal plasma DNA in 113 cases of fetal nuchal cystic hygroma.

Obstet Gynecol

Mother Infant Research Institute at Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts; the Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota; the Center for Fetal Medicine and Women's Ultrasound and the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; the Prenatal Diagnosis Center, San Francisco Perinatal Associates, San Francisco, California; Eastern Virginia Medical School, Norfolk, Virginia; and Verinata Health, Inc, Redwood City, California.

Published: May 2013

Objective: To estimate the accuracy and potential clinical effect of using massively parallel sequencing of maternal plasma DNA to detect fetal aneuploidy in a cohort of pregnant women carrying fetuses with nuchal cystic hygroma.

Methods: The MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) study database was queried to identify eligible patients carrying fetuses with cystic hygroma (n=113) based on clinical ultrasonographic examination reports near enrollment. Archived plasma samples were newly sequenced and normalized chromosome values were determined. Aneuploidy classifications for chromosomes 21, 18, 13, and X were made using the massively parallel sequencing data by laboratory personnel blinded to fetal karyotype and compared for analysis.

Results: : Sixty-nine of 113 (61%) patients had fetuses with abnormal karyotypes, including trisomy 21 (n=30), monosomy X (n=21), trisomy 18 (n=10), trisomy 13 (n=4), and other (n=4). There were 44 euploid cases; none was called positive for aneuploidy. The massively parallel sequencing detection rates were as follows: T21: 30 of 30, T18: 10 of 10, T13: three of four, and monosomy X: 20 of 21, including two complex mosaic cases. Overall, using massively parallel sequencing results of the four studied chromosomes, 107 of 113 (95%, 95% confidence interval [CI] 88.8-98.0) cases were accurately called by massively parallel sequencing, including 63 of 65 (97%, 95% CI 89.3-99.6) of cases of whole chromosome aneuploidy.

Conclusion: : Massively parallel sequencing provides an accurate way of detecting the most prevalent aneuploidies associated with cystic hygroma. Massively parallel sequencing could advance prenatal care by providing alternative point-of-care noninvasive testing for pregnant women who either decline or do not have access to an invasive procedure.

Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01122524.

Level Of Evidence: II.

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0b013e31828ba3d8DOI Listing

Publication Analysis

Top Keywords

massively parallel
32
parallel sequencing
32
cystic hygroma
12
massively
8
sequencing
8
sequencing maternal
8
maternal plasma
8
plasma dna
8
nuchal cystic
8
fetal aneuploidy
8

Similar Publications

No genetic link between E. coli isolates carrying mcr-1 in bovines and humans in France.

J Glob Antimicrob Resist

January 2025

Institut National de la Santé et de la Recherche Médicale (UMR 1071), Institut National de la Recherche Agronomique (USC-2018), Université Clermont Auvergne, Clermont-Ferrand, France; Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire, Clermont-Ferrand, France.

Background: Colistin is a last-line antibiotic used to treat severe human infections caused by carbapenemase-producing Gram-negative bacteria. In parallel, colistin has massively been used in the veterinary field so that mcr-1-positive E. coli have spread worldwide in livestock, potentially constituting a reservoir of colistin-resistant isolates that can be further transmitted to humans.

View Article and Find Full Text PDF

Innovations in Short-Read Sequencing Technologies and Their Applications to Clinical Genomics.

Clin Chem

January 2025

Division of Genomic and Molecular Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States.

Background: Massively parallel sequencing (MPS) of nucleic acids has been a transformative technology for basic and applied genomic science, increasing efficiencies and decreasing costs to enable studies of unprecedented scope and impact. In clinical settings, these technological and scientific advances have led to the development of tests that are increasingly fast, comprehensive, and more frequently employed. Practitioners of genomic medicine have applied these tools across clinical settings, including diagnosis of inherited disorders and cancers and infectious disease detection and surveillance.

View Article and Find Full Text PDF
Article Synopsis
  • Despite significant advancements in DNA sequencing technologies, clear and concise genomic fingerprints for different species remain elusive.
  • The concept of "nucleic quasi-primes" is introduced as the shortest unique sequences found in specific genomes that can provide insights into species evolution and have applications in various fields like agriculture and healthcare.
  • In humans, nucleic quasi-primes are linked to genes related to brain development, and their presence is associated with variations in gene expression relevant to cognitive function and various diseases.
View Article and Find Full Text PDF

The cis-regulatory elements encoded in an mRNA determine its stability and translational output. While there has been a considerable effort to understand the factors driving mRNA stability, the regulatory frameworks governing translational control remain more elusive. We have developed a novel massively parallel reporter assay (MPRA) to measure mRNA translation, named Nascent Peptide Translating Ribosome Affinity Purification (NaP-TRAP).

View Article and Find Full Text PDF

The highly rugged yet navigable regulatory landscape of the bacterial transcription factor TetR.

Nat Commun

December 2024

Department of Evolutionary Biology and Environmental Studies, University of Zurich, Winterthurerstrasse 190, Zurich, CH-8057, Switzerland.

Transcription factor binding sites (TFBSs) are important sources of evolutionary innovations. Understanding how evolution navigates the sequence space of such sites can be achieved by mapping TFBS adaptive landscapes. In such a landscape, an individual location corresponds to a TFBS bound by a transcription factor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!